Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG).


Journal

Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 24 11 2020
accepted: 03 04 2021
pubmed: 29 4 2021
medline: 21 10 2021
entrez: 28 4 2021
Statut: ppublish

Résumé

Local recurrence following resection of retroperitoneal liposarcoma (RLPS) is common. Well-differentiated (WD) and dedifferentiated (DD) RLPS are distinct entities with differing outcomes. A few reports suggest that WDLPS can recur as DDLPS and that DDLPS can recur as WDLPS. This study evaluates whether this change in differentiation from the primary tumor to the first local recurrence impacts long-term outcomes. Retrospective review from 22 sarcoma centers identified consecutive patients who underwent resection for a first locally recurrent RLPS from January 2002 to December 2011. Outcomes measured included overall survival, local recurrence, and distant metastasis. A total of 421 RPLS patients were identified. Of the 230 patients with primary DDLPS, 34 (15%) presented WDLPS upon recurrence (DD → WD); and of the 191 patients with primary WDLPS, 54 (28%) presented DDLPS upon recurrence (WD → DD). The 6-year overall survival probabilities (95% CI) for DD → DD, DD → WD, WD → WD, and WD → DD were 40% (32-48%), 73% (58-92%), 76% (68-85%), and 56% (43-73%) (p < 0.001), respectively. The 6-year second local recurrence incidence was 66% (59-73%), 63% (48-82%), 66% (57-76%), and 77% (66-90%), respectively. The 6-year distant metastasis incidence was 13% (9-19%), 3% (0.4-22%), 5% (2-11%), and 4% (1-16%), respectively. On multivariable analysis, DD → WD was associated with improved overall survival when compared with DD → DD (p < 0.001). Moreover, WD → DD was associated with a higher risk of LR (p = 0.025) CONCLUSION: A change in RLPS differentiation from primary tumor to first local recurrence appears to impact survival. These findings may be useful in counseling patients on their prognosis and subsequent management.

Sections du résumé

BACKGROUND BACKGROUND
Local recurrence following resection of retroperitoneal liposarcoma (RLPS) is common. Well-differentiated (WD) and dedifferentiated (DD) RLPS are distinct entities with differing outcomes. A few reports suggest that WDLPS can recur as DDLPS and that DDLPS can recur as WDLPS. This study evaluates whether this change in differentiation from the primary tumor to the first local recurrence impacts long-term outcomes.
METHODS METHODS
Retrospective review from 22 sarcoma centers identified consecutive patients who underwent resection for a first locally recurrent RLPS from January 2002 to December 2011. Outcomes measured included overall survival, local recurrence, and distant metastasis.
RESULTS RESULTS
A total of 421 RPLS patients were identified. Of the 230 patients with primary DDLPS, 34 (15%) presented WDLPS upon recurrence (DD → WD); and of the 191 patients with primary WDLPS, 54 (28%) presented DDLPS upon recurrence (WD → DD). The 6-year overall survival probabilities (95% CI) for DD → DD, DD → WD, WD → WD, and WD → DD were 40% (32-48%), 73% (58-92%), 76% (68-85%), and 56% (43-73%) (p < 0.001), respectively. The 6-year second local recurrence incidence was 66% (59-73%), 63% (48-82%), 66% (57-76%), and 77% (66-90%), respectively. The 6-year distant metastasis incidence was 13% (9-19%), 3% (0.4-22%), 5% (2-11%), and 4% (1-16%), respectively. On multivariable analysis, DD → WD was associated with improved overall survival when compared with DD → DD (p < 0.001). Moreover, WD → DD was associated with a higher risk of LR (p = 0.025) CONCLUSION: A change in RLPS differentiation from primary tumor to first local recurrence appears to impact survival. These findings may be useful in counseling patients on their prognosis and subsequent management.

Identifiants

pubmed: 33907921
doi: 10.1245/s10434-021-10024-y
pii: 10.1245/s10434-021-10024-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7854-7863

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

© 2021. Society of Surgical Oncology.

Références

Bagaria SP, Gabriel E, Mann GN. Multiply recurrent retroperitoneal liposarcoma. J Surg Oncol. 2018;117:62–8.
doi: 10.1002/jso.24929
Gronchi A, Strauss DC, Miceli R. Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative RPS working group. Ann Surg. 2016;263(5):1002–9.
doi: 10.1097/SLA.0000000000001447
Linehan DC, Lewis JJ, Leung D, Brennan MF. Influence of biologic factors and anatomic site in completely resected liposarcoma. J Clin Oncol. 2000;18:1637–43.
doi: 10.1200/JCO.2000.18.8.1637
Park JO, Qin LX, Prete FP, Antonescu C, Brennan MF, Singer S. Predicting outcome by growth rate of locally recurrent retroperitoneal liposarcoma: the one centimeter per month rule. Ann Surg. 2009;250:977–82.
doi: 10.1097/SLA.0b013e3181b2468b
Hamilton TD, Cannell AJ, Kim M, et al. Results of resection for recurrent or residual retroperitoneal sarcoma after failed primary treatment. Ann Surg Oncol. 2017;24:211–8.
doi: 10.1245/s10434-016-5523-6
Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003;238:358–370. discussion 70-1.
Tseng WW, Madewell JE, Wei W, et al. Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection? Ann Surg Oncol. 2014;21:2136–43.
doi: 10.1245/s10434-014-3643-4
Tan MC, Brennan MF, Kuk D, et al. Histology-based classification predicts pattern of recurrence and improves risk stratification in primary retroperitoneal sarcoma. Ann Surg. 2016;263:593–600.
doi: 10.1097/SLA.0000000000001149
Lahat G, Anaya DA, Wang X, Tuvin D, Lev D, Pollock RE. Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches. Ann Surg Oncol. 2008;15:1585–93.
doi: 10.1245/s10434-007-9805-x
Dei Tos AP. Liposarcomas: diagnostic pitfalls and new insights. Histopathology. 2014;64:38–52.
doi: 10.1111/his.12311
Chan RP, Callegaro D, Miceli R, et al. Predicting survival in patients undergoing resection for locally recurrent retroperitoneal sarcoma: a study and novel nomogram from TARPSWG. Clin Cancer Res. 2019;25(8):2664–71.
doi: 10.1158/1078-0432.CCR-18-2700
Agresti Alan. Categorical data analysis. New York: Wiley; 1990. p. 350–4.
Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37(3/4):256–66.
doi: 10.2307/2332378
MacNeill AJ, Gronchi A, Micelli R, et al. Postoperative morbidity after radical resection of primary retroperitoneal sarcoma a report from the transatlantic RPS working group. Ann Surg Oncol. 2017;24:688–9.
doi: 10.1245/s10434-017-5889-0
Schemper M, Smith TL. A note on quantifying follow-up studies of failure time. Control Clin Trials. 1996;17:343–6.
doi: 10.1016/0197-2456(96)00075-X
Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8:551–61.
doi: 10.1002/sim.4780080504
Evans HL. Liposarcoma a study of 55 cases with a reassessment of its classification. Am J Surg Pathol. 1979;3:507–23.
doi: 10.1097/00000478-197912000-00004

Auteurs

Carolyn Nessim (C)

Department of Surgery, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada. cnessim@toh.ca.

Chandrajit P Raut (CP)

Department of Surgery, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA, USA.

Dario Callegaro (D)

Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Francesco Barretta (F)

Department of Applied Research and Technological Development, Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Rosalba Miceli (R)

Department of Applied Research and Technological Development, Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Mark Fairweather (M)

Department of Surgery, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA, USA.

Jean-Yves Blay (JY)

Department of Medical Oncology, Center Léon Bérard Cancer Center, Lyon, France.

Dirk Strauss (D)

Department of Surgery, Royal Marsden Hospital NHS Foundation Trust, London, UK.

Piotr Rutkowski (P)

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.

Nita Ahuja (N)

Department of Surgery, Yale School of Medicine, New Haven, CT, USA.
John Hopkins University School of Medicine, Baltimore, MD, USA.

Ricardo Gonzalez (R)

Department of Surgery, Moffitt Cancer Center, Tampa, FL, USA.

Giovanni Grignani (G)

Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, TO, Italy.

Vittorio Quagliuolo (V)

Department of Surgery, Istituto Clinico Humanitas IRCCS, Milan, Italy.

Eberhard Stoeckle (E)

Department of Surgery, Institut Bergonié, Bordeaux, France.

Guy Lahat (G)

Department of Surgery, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.

Antonino De Paoli (A)

Department of Radiation Oncology, Centro di Riferimento Oncologico, Aviano, Italy.

Venu G Pillarisetty (VG)

Department of Surgery, University of Washington School of Medicine, Seattle, WA, USA.

Robert J Canter (RJ)

Department of Surgery, UC Davis Health, Sacramento, CA, USA.

John T Mullen (JT)

Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.

Elisabetta Pennacchioli (E)

Division of Melanoma, Sarcomas and Rare Tumors, IEO, European Institute of Oncology, IRCCS, Milan, Italy.

Winan van Houdt (W)

Department of Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Carol J Swallow (CJ)

Department of Surgery, Mount Sinai Hospital and Princess Margaret Cancer Center, Toronto, Canada.

Yvonne Schrage (Y)

Department of Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Department of Surgery, Mount Sinai Hospital and Princess Margaret Cancer Center, Toronto, Canada.
Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.

Kenneth Cardona (K)

Department of Surgery, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.

Marco Fiore (M)

Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Alessandro Gronchi (A)

Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Sanjay P Bagaria (SP)

Department of Surgery, Mayo Clinic, Jacksonville, FL, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH